Trial Information
A Phase I/II study to determine the maximum tolerated dose (MTD) and to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of antroquinonol in combination with nab-paclitaxel and gemcitabine in first line metastatic pancreatic cancer
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
